慢性髓性白血病管理中挑战性问题的处理:何时可安全停用酪氨酸激酶抑制剂?
该综述讨论慢性髓性白血病(CML)治疗范式从终身靶向治疗向无治疗缓解的演变。基于多项独立临床试验证据,深度且持续分子学缓解的患者可安全停用BCR-ABL1酪氨酸激酶抑制剂(TKI)。文章依据最新最佳证据探讨临床实践中安全停用TKI的时机。
要点
- CML治疗目标已从终身TKI治疗转变为追求持续无治疗缓解。
- 多项独立临床试验证实深度持续分子学缓解者停用TKI可行。
- 临床实践中停用TKI需基于最佳最新证据选择合适时机。
核心结论
- CML治疗范式正从终身TKI治疗向实现持续无治疗缓解演变。
- 深度且持续分子学缓解的患者停用TKI是可行的。
研究设计与样本
- 本文为综述,基于多项独立临床试验及最新最佳证据讨论TKI停用时机。
主要发现
- 多项独立临床试验提供了TKI停用可行的确凿证据,对象为深度且持续分子学缓解的CML患者。
临床怎么用
- 临床实践中应依据最佳最新证据,在深度持续分子学缓解患者中评估安全停用TKI的时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The paradigm for managing patients with chronic myeloid leukemia is evolving. In the recent past, restoring a normal life expectancy while patients are receiving never-ending targeted therapy with BCR-ABL1 tyrosine kinase inhibitors through prevention of progression to blast phase and mitigation of iatrogenic risks was considered the best achievable outcome. Now, long-term treatment-free remission with continued response off tyrosine kinase inhibitor therapy is recognized as the most optimal benefit of treatment. Indeed, numerous independent clinical trials provided solid proof that tyrosine kinase inhibitor discontinuation was feasible in patients with deep and sustained molecular responses. This article discusses when tyrosine kinase inhibitors may be safely stopped in clinical practice on the basis of the best and latest available evidence.
引用
- Rea D. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? Blood Adv. 2020. PMID: 33170936. doi:10.1182/bloodadvances.2020002538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。